Dermapharm Holding SE

XETRA DMP.DE

Dermapharm Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 225.76 M

Dermapharm Holding SE Net Cash Used Provided By Financing Activities is USD 225.76 M for the year ending December 31, 2023, a 205.62% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Dermapharm Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -213.74 M, a -131.87% change year over year.
  • Dermapharm Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD -92.18 M, a -435.57% change year over year.
  • Dermapharm Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD -17.21 M, a -108.34% change year over year.
  • Dermapharm Holding SE Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 206.45 M, a 9.69% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
XETRA: DMP.DE

Dermapharm Holding SE

CEO Dr. Hans-Georg Feldmeier
IPO Date April 12, 2018
Location Germany
Headquarters Lil-Dagover-Ring 7
Employees 3,603
Sector Health Care
Industries
Description

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

StockViz Staff

January 15, 2025

Any question? Send us an email